Experienced in Burkitt Lymphoma

Dr. Roland B. Walter

Hematology
The Association Of University Physicians
1959 Ne Pacific St, 
Seattle, WA 
Accepting New Patients
Offers Telehealth
26 Years of Experience
Experienced in Burkitt Lymphoma
The Association Of University Physicians
1959 Ne Pacific St, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Roland Walter is a Hematologist in Seattle, Washington. Dr. Walter has been practicing medicine for over 26 years and is rated as an Experienced provider by MediFind in the treatment of Burkitt Lymphoma. His top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Febrile Neutropenia, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Walter is currently accepting new patients.

His clinical research consists of co-authoring 286 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 2 articles in the study of Burkitt Lymphoma.

Specialties
Hematology
Licenses
Internal Medicine in WA
Hospital Affiliations
University Of Washington Medical Ctr
Languages Spoken
English
Arabic
Filipino
French
German
Hindi
Mandarin
Punjabi
Spanish
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

PacificSource
  • PPO
Premera
  • EPO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

THE ASSOCIATION OF UNIVERSITY PHYSICIANS
1959 Ne Pacific St, Seattle, WA 98195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination With Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia
A Phase I Study to Evaluate the Safety and Tolerability of Gemtuzumab Ozogamicin and Midostaurin When Used in Combination With Standard Cytarabine and Daunorubicin Induction for Newly Diagnosed FLT3-mutated Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: October 28, 2025
Intervention Type: Procedure, Drug
Study Drugs: Cytarabine, Daunorubicin Hydrochloride, Gemtuzumab Ozogamicin, Midostaurin
Study Phase: Phase 1
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
A Phase 1b/2 Study of IMGN632 as Monotherapy or Combination With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia
Enrollment Status: Active_not_recruiting
Publish Date: August 14, 2025
Intervention Type: Drug
Study Drugs: Azacitidine, IMGN632, Venetoclax
Study Phase: Phase 1/Phase 2
A Long-term Follow-up Study of Patients Who Received VOR33
A Long-term Follow-up Study of Patients Who Received VOR33
Enrollment Status: Terminated
Publish Date: July 29, 2025
Intervention Type: Genetic
A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
A First-In-Human, Open-Label, Multicenter Study of VOR33 in Patients With Acute Myeloid Leukemia Who Are at High-Risk for Leukemia Relapse Following Hematopoietic Cell Transplantation
Enrollment Status: Terminated
Publish Date: July 29, 2025
Intervention Type: Biological, Drug
Study Drugs: VOR33, Mylotarg
Study Phase: Phase 1/Phase 2
Randomized Phase 2 Trial of CPX-351 (Vyxeos) vs. CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less-Fit Adults With Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm
Randomized Phase 2 Trial of CPX-351 (Vyxeos) vs. CLAG-M (Cladribine, Cytarabine, G-CSF, and Mitoxantrone) in Medically Less-Fit Adults With Acute Myeloid Leukemia (AML) or Other High-Grade Myeloid Neoplasm
Enrollment Status: Active_not_recruiting
Publish Date: July 10, 2025
Intervention Type: Other, Biological, Drug
Study Drugs: Liposomal Daunorubicin, Liposomal Cytarabine, Cladribine, Cytarabine, Granulocyte Colony-Stimulating Factor, Mitoxantrone
Study Phase: Phase 2
A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients With CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: December 16, 2024
Intervention Type: Drug
Study Drug: IMGN-632 CD123-Targeting Antibody-Drug Conjugate
Study Phase: Phase 1/Phase 2
A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR
Enrollment Status: Terminated
Publish Date: October 17, 2024
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Single-Center Phase 1/2 Study of Single- or Fractioned-Dose Gemtuzumab Ozogamicin in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone for Previously Untreated Adult Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm
A Single-Center Phase 1/2 Study of Single- or Fractioned-Dose Gemtuzumab Ozogamicin in Combination With G-CSF, Cladribine, Cytarabine, and Mitoxantrone for Previously Untreated Adult Acute Myeloid Leukemia or High-Grade Myeloid Neoplasm
Enrollment Status: Completed
Publish Date: August 30, 2023
Intervention Type: Biological, Drug, Other
Study Drugs: Cladribine, Cytarabine, Gemtuzumab, Granulocyte Colony-Stimulating Factor, Mitoxantrone
Study Phase: Phase 1/Phase 2
A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia
A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia
Enrollment Status: Terminated
Publish Date: February 26, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
A Phase 1/2 Trial of G-CSF, Cladribine, Cytarabine, and Dose-Escalated Mitoxantrone (G-CLAM) in Adults With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)
Enrollment Status: Completed
Publish Date: January 10, 2020
Intervention Type: Biological, Drug, Other
Study Phase: Phase 1/Phase 2
Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality
Liposomal Cytarabine and Daunorubicin (CPX-351) for Adults With Untreated High-Risk MDS and Non-APL AML at High Risk of Treatment-Related Mortality
Enrollment Status: Completed
Publish Date: May 25, 2018
Intervention Type: Drug, Other
Study Phase: Not Applicable
A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
A Phase 1 Study of SGN-CD123A in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: May 14, 2018
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
A Phase 1b Dose-escalation Study of SGN-CD33A in Combination With Standard-of-care for Patients With Newly Diagnosed Acute Myeloid Leukemia
Enrollment Status: Completed
Publish Date: May 09, 2018
Intervention Type: Drug
Study Phase: Phase 1
View 12 Less Clinical Trials

286 Total Publications

Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.
Ziftomenib in Relapsed or Refractory NPM1-Mutated AML.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 25, 2025
Similar Doctors
Advanced in Burkitt Lymphoma
Dr. Chaitra Ujjani
Hematology | Oncology
Advanced in Burkitt Lymphoma
Dr. Chaitra Ujjani
Hematology | Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (1.9 miles away)
206-288-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Chaitra Ujjani is a Hematologist and an Oncologist in Seattle, Washington. Dr. Ujjani is rated as an Elite provider by MediFind in the treatment of Burkitt Lymphoma. Her top areas of expertise are Chronic B-Cell Leukemia (CBCL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Bone Marrow Aspiration, and Bone Marrow Transplant.

Ryan D. Cassaday
Advanced in Burkitt Lymphoma
Dr. Ryan D. Cassaday
Hematology Oncology | Hematology | Oncology
Advanced in Burkitt Lymphoma
Dr. Ryan D. Cassaday
Hematology Oncology | Hematology | Oncology

The Association Of University Physicians

825 Eastlake Ave E, 
Seattle, WA 
 (1.9 miles away)
206-288-1000
Languages Spoken:
English, Mandarin, Spanish, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Ryan Cassaday is a Hematologist Oncology specialist and a Hematologist in Seattle, Washington. Dr. Cassaday is rated as an Elite provider by MediFind in the treatment of Burkitt Lymphoma. His top areas of expertise are Acute Lymphoblastic Leukemia (ALL), Leukemia, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Cassaday is currently accepting new patients.

Advanced in Burkitt Lymphoma
Dr. Jacob E. Mathew
Hematology | Oncology
Advanced in Burkitt Lymphoma
Dr. Jacob E. Mathew
Hematology | Oncology

Franciscan Medical Group

2720 Clare Ave, Suite A, 
Bremerton, WA 
 (15.6 miles away)
360-479-6154
Languages Spoken:
English, Farsi, Vietnamese
See accepted insurances
Accepting New Patients
Offers Telehealth

Jacob Mathew is a Hematologist and an Oncologist in Bremerton, Washington. Dr. Mathew is rated as a Distinguished provider by MediFind in the treatment of Burkitt Lymphoma. His top areas of expertise are Small Cell Lung Cancer (SCLC), Lung Adenocarcinoma, Pleuropulmonary Blastoma, Osteotomy, and Bone Marrow Aspiration. Dr. Mathew is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Walter's expertise for a condition
ConditionClose
View All 24 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile